

## CLAIMS


1. Use of an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, in the preparation of a medicine for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



**(I)**









**(II)**



**(III)**

wherein:

$B^{1A}$ is elected from the group consisting of:


,

,

,

,

and

;

wherein:

$R^{A2}$ is selected from the group consisting of hydrogen, halogen and $NHR^{J2}$, wherein $R^{J2}$ is hydrogen;

$R^{B2}$ is halogen or $NHR^{W2}$, wherein $R^{W2}$ is hydrogen;

$R^{C2}$ is hydrogen or $NHR^{O2}$, wherein $R^{O2}$ is hydrogen;

$R^{D2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$ alkyl;

$R^{E2}$ is selected from the group consisting of hydrogen, hydroxy and an unsubstituted $C_{1-6}$ alkyl;

$R^{F2}$ is selected from the group consisting of hydrogen, halogen, and an unsubstituted $C_{1-6}$alkyl;


$Y^2$ is N;


$Y^3$ is N or $CR^{I2}$, wherein $R^{I2}$ is hydrogen;


$R^{G2}$ is an unsubstituted $C_{1-6}$ alkyl; and


$R^{H2}$ is hydrogen or $NHR^{T2}$, wherein $R^{T2}$ is hydrogen;


$B^{1B}$ is selected from the group consisting of:




,


,


,


,


and


;

wherein:

$R^{AB2}$ is selected from the group consisting of hydrogen, halogen and $NHR^{JB2}$, wherein $R^{JB2}$ is hydrogen;

$R^{BB2}$ is halogen or $NHR^{WB2}$, wherein $R^{WB2}$ is hydrogen;

$R^{CB2}$ is hydrogen or $NHR^{OB2}$, wherein $R^{OB2}$ is hydrogen;

$R^{DB2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$ alkyl;

$R^{EB2}$ is selected from the group consisting of hydrogen, hydroxy and an unsubstituted $C_{1-6}$ alkyl;

$R^{FB2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$alkyl;







$Y^{2B}$ is N;

$Y^{3B}$ is $CR^{IB2}$, wherein $R^{IB2}$ is hydrogen;

$R^{GB2}$ is an unsubstituted $C_{1-6}$ alkyl; and

$R^{HB2}$ is hydrogen or $NHR^{TB2}$, wherein $R^{TB2}$ is hydrogen;

$B^{1C}$ is selected from the group consisting of:


,

,

,

,

and

;

wherein:

$R^{AC2}$ is selected from the group consisting of hydrogen, halogen and $NHR^{JC2}$, wherein $R^{JC2}$ is hydrogen,;

$R^{BC2}$ is halogen or $NHR^{WC2}$, wherein $R^{WC2}$ is hydrogen;

$R^{CC2}$ is hydrogen or $NHR^{OC2}$, wherein $R^{OC2}$ is hydrogen;

$R^{DC2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$ alkyl;

$R^{EC2}$ is selected from the group consisting of hydrogen, hydroxy and an unsubstituted $C_{1-6}$ alkyl;



$R^{FC2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$ alkyl;


$Y^{2C}$ is N;

$Y^{3C}$ is $CR^{IC2}$, wherein $R^{IC2}$ is hydrogen;

$R^{GC2}$ is an unsubstituted $C_{1-6}$ alkyl; and

$R^{HC2}$ is hydrogen or $NHR^{TC2}$, wherein $R^{TC2}$ is hydrogen;

$R^{1A}$ is selected from the group consisting of hydrogen, an optionally substituted acyl,  


an optionally substituted O-linked α–amino acid,  and


;


the dashed line (------) of Formula (I) is absent;


$R^{2A}$ is selected from the group consisting of an unsubstituted $C_{1-6}$ alkyl, a halogen substituted $C_{1-6}$ alkyl, a hydroxy substituted $C_{1-6}$ alkyl, an alkoxy substituted $C_{1-6}$ alkyl, a sulfenyl substituted $C_{1-6}$ alkyl, an optionally substituted $C_{2-6}$ alkenyl, an optionally substituted $C_{2-6}$ alkynyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted –O–$C_{1-6}$ alkyl and cyano;

$R^{3A}$ is selected from the group consisting of OH, –OC(=O)$R^{"A}$ and an optionally substituted O-linked α-amino acid;

$R^{1B}$ is selected from the group consisting of $O^-$, OH,  and

 ;

$R^{1C}$ and $R^{2C}$ are independently selected from the group consisting of $O^-$, OH, an optionally substituted $C_{1-6}$ alkoxy, and  ; or

$R^{1C}$ is  and $R^{2C}$ is $O^-$ or OH;


$R^{2B}$ and $R^{3C}$ are independently an optionally substituted $C_{1-6}$ alkyl;

$R^{4C}$ is OH;


$R^{4A}$, $R^{3B}$ and $R^{5C}$ are independently a halogen;

$R^{5A}$, $R^{4B}$ and $R^{6C}$ are independently hydrogen or halogen;

$R^{6A}$, $R^{7A}$ and $R^{8A}$ are independently selected from the group consisting of absent, hydrogen, optionally substituted aryl, an optionally substituted heteroaryl,




and




; or

$R^{6A}$ is




and $R^{7A}$ is absent or hydrogen; or

$R^{6A}$ and $R^{7A}$ are taken together to form a moiety selected from the group consisting of an optionally substituted



and an optionally substituted



, wherein the oxygens connected to $R^{6A}$ and $R^{7A}$, the phosphorus and the moiety form a six-membered to ten-membered ring system;

$R^{9A}$ is an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative;

$R^{10A}$ and $R^{11A}$ are independently an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative;

$R^{12A}$, $R^{13A}$ and $R^{14A}$ are independently absent or hydrogen;

$R^{22A}$, $R^{23A}$, $R^{8B}$, $R^{9B}$, $R^{12C}$ and $R^{13C}$ are independently hydrogen or an unsubstituted $C_{1-4}$ alkyl;

$R^{24A}$, $R^{10B}$ and $R^{14C}$ are independently selected from the group consisting of hydrogen, an optionally substituted $C_{1-24}$ alkyl and an optionally substituted –O–$C_{1-24}$ alkyl;

$R^{25A}$ and $R^{11B}$ are independently hydrogen or an optionally substituted $C_{1-24}$ alkyl;

$R^{16C}$, $R^{17C}$ and $R^{18C}$ are independently absent or hydrogen;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each $R^{7C}$ and each $R^{8C}$ is independently hydrogen or halogen; and


when ------- is a double bond, each $R^{7C}$ is absent and each $R^{8C}$ is independently hydrogen or halogen;

$R"^{A}$ and $R"^{C}$ are independently an optionally substituted $C_{1-24}$-alkyl;

m and n are independently 0 or 1;

$Z^{1A}$, $Z^{2A}$ and $Z^{3A}$, are independently O or S

$Z^{4A}$, $Z^{1B}$, $Z^{2B}$ and $Z^{1C}$ are O; and



provided that when $R^{1A}$ is wherein $R^{8A}$ is phenyl optionally para-substituted with a halogen or methyl and $R^{9A}$ is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an α–amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro or hydrogen; and $B^{1A}$ is an unsubstituted uracil; then $R^{2A}$ cannot be $-OCH_3$;

provided that when $R^{1A}$ is H; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro; and $B^{1A}$ is an unsubstituted cytosine; then $R^{2A}$ cannot be allenyl; and

provided that when $R^{1A}$ is H; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro; and $B^{1A}$ is an unsubstituted cytosine; then $R^{2A}$ cannot be ethynyl; and

a heteroaryl is a 4 to 14 atoms monocyclic or multicyclic aromatic ring system that contains one or more heteroatoms selected from nitrogen, oxygen and sulfur; and

when a substituent is indicated as optionally substituted. the substituent may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, an amino, a mono-substituted amino group and a di-substituted amino group;

2. The use of Claim 1, wherein the virus is a henipavirus, a morbillivirus and/or a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.

6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.




7. The use of Claim 1, wherein the virus is a rubulavirus.

8. The use of Claim 7, wherein the rubulavirus is human parainfluenza virus 2 and/or human parainfluenza virus 4.


9. The use of Claim 1, wherein the virus is a metapneumovirus.


10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.



11. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (I).






12. The use of Claim 11, wherein $R^{1A}$ is  ,  or  .

13. The use of Claim 12, wherein $R^{6A}$ and $R^{7A}$ are both hydrogen or absent.

14. The use of Claim 12, wherein both $R^{6A}$ and $R^{7A}$ are  .

15. The use of Claim 12, wherein $R^{6A}$ and $R^{7A}$ are both  ;.


16. The use of Claim 12, wherein $R^{6A}$ and $R^{7A}$ can be taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted  , wherein the oxygens connected to $R^{6A}$ and $R^{7A}$, the phosphorus and the moiety form a six-membered to ten-membered ring system; or

wherein $R^{6A}$ and $R^{7A}$ can be taken together to form a moiety selected from the group consisting of  ,  ,  ,  and  , wherein $R^{32A}$ is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

17. The use of any one of Claims 12-16, wherein $Z^{1A}$ is O.

18. The use of any one of Claims 12-16, wherein $Z^{1A}$ is S.

19. The use of Claim 12, wherein $R^{8A}$ is an optionally substituted aryl; and $R^{9A}$ is an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative.


20. The use of Claim 12, wherein $R^{9A}$ is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein $R^{9A}$ is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein $R^{9A}$ has the structure  wherein $R^{33A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$-alkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted aryl, an optionally substituted aryl($C_{1-6}$ alkyl) and an optionally substituted haloalkyl; $R^{34A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{1-6}$ haloalkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted $C_6$ aryl, an optionally substituted $C_{10}$ aryl and an optionally

substituted aryl($C_{1-6}$ alkyl); and $R^{35A}$ is hydrogen or an optionally substituted $C_{1-4}$-alkyl; or $R^{34A}$ and $R^{35A}$ are taken together to form an optionally substituted $C_{3-6}$ cycloalkyl.

21. The use of Claim 20, wherein $R^{34A}$ is an optionally substituted $C_{1-6}$-alkyl; $R^{35A}$ is hydrogen; and $R^{33A}$ is an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{3-6}$ cycloalkyl or an optionally substituted benzyl.

22. The use of any one of Claims 12 or 19-21, wherein $Z^{2A}$ is O.


23. The use of any one of Claims 12 or 19-21, wherein $Z^{2A}$ is S.

24. The use of Claim 12, wherein $R^{10A}$ and $R^{11A}$ are both an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative; or wherein $R^{10A}$ and $R^{11A}$ are independently selected from selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein $R^{10A}$ and $R^{11A}$ are independently selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein $R^{10A}$ and $R^{11A}$ are independently have the structure  wherein $R^{36A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$-alkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted aryl, an optionally substituted aryl($C_{1-6}$ alkyl) and an optionally substituted haloalkyl; $R^{37A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{1-6}$ haloalkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted $C_6$ aryl, an optionally substituted $C_{10}$ aryl and an optionally substituted aryl($C_{1-6}$ alkyl); and $R^{38A}$ is hydrogen or an optionally substituted $C_{1-4}$-alkyl; or $R^{37A}$ and $R^{38A}$ are taken together to form an optionally substituted $C_{3-6}$ cycloalkyl.

25. The use of Claim 24, wherein $R^{37A}$ is an optionally substituted $C_{1-6}$-alkyl; $R^{38A}$ is hydrogen; and $R^{36A}$ is an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{3-6}$ cycloalkyl or an optionally substituted benzyl.

26. The use of any one of Claims 12 or 24-25, wherein $Z^{3A}$ is O.

27. The use of any one of Claims 12 or 24-25, wherein $Z^{3A}$ is S.

28. The use of Claim 12, wherein $R^{6A}$ is  , $R^{7A}$ is absent or hydrogen; m is 0 or 1; and $R^{12A}$, $R^{13A}$ and $R^{14A}$ are independently absent or hydrogen.


29. The use of Claim 28, wherein m is 0, and $R^{12A}$ and $R^{13A}$ are independently absent or hydrogen; or wherein m is 1, and $R^{12A}$, $R^{13A}$ and $R^{14A}$ are independently absent or hydrogen.

30. The use of Claim 11, wherein $R^{1A}$ is H.

31. The use of Claim 11, wherein $R^{1A}$ is an optionally substituted acyl.







32. The use of Claim 31, wherein the optionally substituted acyl is $-C(=O)R^{39A}$, wherein $R^{39A}$ is an optionally substituted $C_{1-12}$ alkyl or an optionally substituted $C_{2-12}$ alkenyl.




33. The use of Claim 32, wherein $R^{39A}$ is an unsubstituted $C_{1-12}$ alkyl.



34. The use of Claim 11, wherein $R^{1A}$ is an optionally substituted O-linked α–amino acid; or wherein $R^{1A}$ is  , wherein $R^{40A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{1-6}$ haloalkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted $C_6$ aryl, an optionally substituted $C_{10}$ aryl and an optionally substituted aryl($C_{1-6}$ alkyl); and $R^{41A}$ is hydrogen or an optionally substituted $C_{1-4}$-alkyl; or $R^{40A}$ and $R^{41A}$ are taken together to form an optionally substituted $C_{3-6}$ cycloalkyl.


35. The use of Claim 34, wherein $R^{40A}$ is an optionally substituted $C_{1-6}$-alkyl; and $R^{41A}$ is hydrogen.

36. The use of any one of Claims 11-35, wherein $B^{1A}$ is selected from the group consisting of:





and

and

.

37. The use of Claim 36, wherein $B^{1A}$ is

,

or

.

38. The use of Claim 36, wherein $B^{1A}$ is

.or


39. The use of Claim 36, wherein $B^{1A}$ is

.

40. The use of any one of Claims 11-39, wherein $R^{2A}$ is a halogen substituted $C_{1-6}$ alkyl or a sulfenyl substituted $C_{1-6}$ alkyl, and $R^{3A}$ is selected from the group consisting of OH, -$OC(=O)R^{"A}$ and an optionally substituted O-linked α–amino acid.

41. The use of any one of Claims 11-39, wherein $R^{2A}$ is an unsubstituted $C_{1-6}$ alkyl.

42. The use of Claim 40, wherein $R^{2A}$ is a halogen substituted $C_{1-6}$ alkyl.


43. The use of one of Claims 11-39, wherein $R^{2A}$ is an optionally substituted $C_{2-6}$ alkenyl, an optionally substituted $C_{2-6}$ alkynyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted –O–$C_{1-6}$ alkyl or cyano.

44. The use of any one of Claims 11-43, wherein $R^{3A}$ is OH.

45. The use of any one of Claims 11-43, wherein $R^{3A}$ is –$OC(=O)R^{"A}$, wherein $R^{"A}$ is an optionally substituted $C_{1-8}$ alkyl.

46. The use of Claim 45, wherein $R^{"A}$ is an unsubstituted $C_{1-8}$ alkyl.

47. The use of any one of Claims 11-43, wherein $R^{3A}$ is O-linked α–amino acid.

48. The use of Claim 47, wherein the O-linked α–amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine; or wherein $R^{3A}$ is  , wherein $R^{42A}$ is selected from the group consisting of hydrogen, an optionally substituted $C_{1-6}$ alkyl, an optionally substituted $C_{1-6}$ haloalkyl, an optionally substituted $C_{3-6}$ cycloalkyl, an optionally substituted $C_6$ aryl, an optionally substituted $C_{10}$ aryl and an optionally substituted aryl($C_{1-6}$ alkyl); and $R^{43A}$ is hydrogen or an optionally substituted $C_{1-4}$-alkyl; or $R^{42A}$ and $R^{43A}$ are taken together to form an optionally substituted $C_{3-6}$ cycloalkyl.

49. The use of Claim 48, wherein $R^{42A}$ is an optionally substituted $C_{1-6}$-alkyl; and $R^{43A}$ is hydrogen.

50. The use of any one of Claims 11-49, wherein $R^{5A}$ is hydrogen.


51. The use of any one of Claims 11-49, wherein $R^{5A}$ is halogen.











52. The use of any one of Claims 11-51, wherein $R^{4A}$ is fluoro.

53. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (II).








54. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (III).

















55. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:


























and
, or a pharmaceutically acceptable salt of the foregoing.

56. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:






















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,













,







,







,

,

,

,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,





,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,


,

,



,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

57. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,

,

,




,




,




,




,




,












,





,





, ,



,

,

, .

,

,

,

,

,

,




























and

, or a pharmaceutically acceptable salt of the foregoing.

58. The use of Claim 11, wherein the compound of Formula (I) is

, or a pharmaceutically acceptable salt thereof.


59. The use of Claim 58, wherein the compound of Formula (I) is

, or a pharmaceutically acceptable salt thereof.

60. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

61. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.


62. The use of Claim 53, wherein the compound of Formula (II) is



,













and





, or a pharmaceutically acceptable salt thereof.

63. The use of Claim 54, wherein the compound of Formula (III) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,




,


and


, or a pharmaceutically acceptable salt of the foregoing.

## CLAIMS


1. Use of an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt of the foregoing, in the manufacture of a medicament for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound of Formula (I), has the structure:




**(I)**

wherein:

$B^{1A}$ is elected from the group consisting of:



and  ;

wherein:

$R^{A2}$ is selected from the group consisting of hydrogen, halogen and $NHR^{J2}$, wherein $R^{J2}$ is hydrogen;

$R^{B2}$ is halogen or $NHR^{W2}$, wherein $R^{W2}$ is hydrogen;

$R^{C2}$ is hydrogen or $NHR^{O2}$, wherein $R^{O2}$ is hydrogen;

$R^{D2}$ is selected from the group consisting of hydrogen, halogen and an unsubstituted $C_{1-6}$ alkyl;

$R^{E2}$ is selected from the group consisting of hydrogen, hydroxy and an unsubstituted $C_{1-6}$ alkyl;


$R^{F2}$ is selected from the group consisting of hydrogen, halogen, and an unsubstituted $C_{1-6}$alkyl;

$Y^2$ is N;

$Y^3$ is N or $CR^{I2}$, wherein $R^{I2}$ is hydrogen;

$R^{G2}$ is an unsubstituted $C_{1-6}$ alkyl; and

$R^{H2}$ is hydrogen or $NHR^{T2}$, wherein $R^{T2}$ is hydrogen;

$R^{1A}$ is selected from the group consisting of hydrogen, $-C(=O)R^{39A}$, an optionally substituted O-linked α–amino acid,  ,  and ;



the dashed line (------) is absent;


$R^{2A}$ is selected from the group consisting of an unsubstituted $C_{1-6}$ alkyl, a halogen substituted $C_{1-6}$ alkyl, a hydroxy substituted $C_{1-6}$ alkyl, an alkoxy substituted $C_{1-6}$ alkyl, a sulfenyl substituted $C_{1-6}$ alkyl, an unsubstituted $C_{2-6}$ alkenyl, an unsubstituted $C_{2-6}$ alkynyl, an unsubstituted $C_{3-6}$ cycloalkyl, an unsubstituted $-O-C_{1-6}$ alkyl and cyano;


$R^{3A}$ is selected from the group consisting of OH, $-OC(=O)R"^{A}$ and an O-linked α-amino acid, wherein the O-linked α-amino acid is selected from the group consisting of O-linked alanine, O-linked asparagine, O-linked aspartate, O-linked cysteine, O-linked glutamate, O-linked glutamine, O-linked glycine, O-linked proline, O-linked serine, O-linked tyrosine, O-linked arginine, O-linked histidine, O-linked isoleucine, O-linked leucine, O-linked lysine, O-linked methionine, O-linked phenylalanine, O-linked threonine, O-linked tryptophan and O-linked valine;


$R^{4A}$ is a halogen;

$R^{5A}$ is hydrogen or halogen,

$R^{6A}$, $R^{7A}$ and $R^{8A}$ are independently selected from the group consisting of absent, hydrogen, an optionally substituted phenyl, an optionally substituted naphthyl,  and  ; or

$R^{6A}$ is  and $R^{7A}$ is absent or hydrogen; or

one of $R^{6A}$ and $R^{7A}$ is  and the other of $R^{6A}$ and $R^{7A}$ is OH or $O^-$;

$R^{6A}$ and $R^{7A}$ are taken together with the oxygens connected to $R^{6A}$ and $R^{7A}$ to form  ;

$R^{9A}$ is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted $C_{1-6}$ alkyl ester, an optionally substituted $C_{3-6}$ cycloalkyl ester, an optionally substituted $C_6$ aryl ester, an optionally substituted $C_{10}$ aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

$R^{10A}$ and $R^{11A}$ are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-

linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted $C_{1-6}$ alkyl ester, an optionally substituted $C_{3-6}$ cycloalkyl ester, an optionally substituted $C_6$ aryl ester, an optionally substituted $C_{10}$ aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

$R^{12A}$, $R^{13A}$ and $R^{14A}$ are independently absent or hydrogen;

$R^{22A}$ and $R^{23A}$ are independently hydrogen or an unsubstituted $C_{1-4}$ alkyl;


$R^{24A}$ is selected from the group consisting of hydrogen, an unsubstituted $C_{1-24}$ alkyl and an unsubstituted –O–$C_{1-24}$ alkyl;

$R^{25A}$ is hydrogen or an unsubstituted $C_{1-24}$ alkyl;

$R^{"A}$ and $R^{39A}$ are independently an unsubstituted $C_{1-24}$-alkyl;

m and n are independently 0 or 1;

$Z^{1A}$, $Z^{2A}$, $Z^{3A}$ and $Z^{4A}$ are O; and

provided that when $R^{1A}$ is  wherein $R^{8A}$ is phenyl optionally para-substituted with a halogen or methyl and $R^{9A}$ is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an α–amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro or hydrogen; and $B^{1A}$ is an unsubstituted uracil; then $R^{2A}$ cannot be $–OCH_3$;

provided that when $R^{1A}$ is H; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro; and $B^{1A}$ is an unsubstituted cytosine; then $R^{2A}$ cannot be allenyl; and

provided that when $R^{1A}$ is H; $R^{3A}$ is OH; $R^{4A}$ is fluoro; $R^{5A}$ is fluoro; and $B^{1A}$ is an unsubstituted cytosine; then $R^{2A}$ cannot be ethynyl; and

a heteroaryl is a 4 to 14 atoms monocyclic or multicyclic aromatic ring system that contains one or more heteroatoms selected from nitrogen, oxygen and sulfur; and

when a substituent is indicated as optionally substituted. the substituent may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, haloalkyl, haloalkoxy, an amino, a mono-substituted amino group and a di-substituted amino group;

2. The use of Claim 1, wherein the virus is selected from the group consisting of a henipavirus, a morbillivirus and a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.



6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.

7. The use of Claim 1, wherein the virus is a rubulavirus.


8. The use of Claim 7, wherein the rubulavirus is selected from the group consisting of human parainfluenza virus 2 and human parainfluenza virus 4.


9. The use of Claim 1, wherein the virus is a metapneumovirus.

10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.

11. The use of any one of Claims 1-10, wherein $R^{1A}$ is  , ,  or .

12. The use of Claim 11, wherein $R^{6A}$ and $R^{7A}$ are both hydrogen or absent.

13. The use of Claim 11, wherein $R^{6A}$ and $R^{7A}$ are both  .

14. The use of Claim 11, wherein $R^{6A}$ and $R^{7A}$ are both  ;.

15. The use of Claim 11, wherein $R^{8A}$ is an optionally substituted phenyl; and $R^{9A}$ is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted $C_{1-6}$ alkyl ester, an optionally substituted $C_{3-6}$ cycloalkyl ester, an optionally substituted $C_6$ aryl ester, an optionally substituted $C_{10}$ aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine.

16. The use of Claim 11, wherein $R^{9A}$ is selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.


17. The use of Claim 16, wherein $R^{9A}$ is selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.

18. The use of Claim 11, wherein $R^{10A}$ and $R^{11A}$ are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted $C_{1-6}$ alkyl ester, an optionally substituted $C_{3-6}$ cycloalkyl ester, an optionally substituted $C_6$ aryl ester, an optionally substituted $C_{10}$ aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked

lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine

19. The use of Claim 18, wherein $R^{10A}$ and $R^{11A}$ are independently selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.

20. The use of Claim 18, wherein $R^{10A}$ and $R^{11A}$ are independently selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.

21. The use of Claim 11, wherein $R^{6A}$ is  ; $R^{7A}$ is absent or hydrogen; m is 0; and $R^{12A}$ and $R^{13A}$ are independently absent or hydrogen.

22. The use of Claim 11, wherein m is 1; and $R^{12A}$, $R^{13A}$ and $R^{14A}$ are independently absent or hydrogen.

23. The use of any one of Claims 1-10, wherein $R^{1A}$ is H.







24. The use of any one of Claims 1-10, wherein $R^{1A}$ is $-C(=O)R^{39A}$.




25. The use of Claim 24, wherein $R^{39A}$ is an unsubstituted $C_{1-12}$ alkyl.



26. The use of any one of Claims 1-10, wherein $R^{1A}$ is an optionally substituted O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.


27. The use of Claim 26, wherein $R^{1A}$ is O-linked alanine or O-linked valine.

28. The use of any one of Claims 1-27, wherein $B^{1A}$ is selected from the group consisting of:





and

and

, wherein $R^{G2}$ is an unsubstituted $C_{1-6}$ alkyl; and $R^{H2}$ is hydrogen or $NHR^{T2}$, wherein $R^{T2}$ is hydrogen.

29. The use of Claim 28, wherein $B^{1A}$ is

,

or

, wherein $R^{G2}$ is an unsubstituted $C_{1-6}$ alkyl; and $R^{H2}$ is hydrogen or $NHR^{T2}$, wherein $R^{T2}$ is hydrogen.

30. The use of Claim 28, wherein $B^{1A}$ is

or


31. The use of Claim 28, wherein $B^{1A}$ is

.

32. The use of any one of Claims 1-31, wherein $R^{2A}$ is a halogen substituted $C_{1-6}$ alkyl or a sulfenyl substituted $C_{1-6}$ alkyl, and $R^{3A}$ is selected from the group consisting of OH, -OC(=O)$R^{"A}$ and an O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.

33. The use of any one of Claims 1-31, wherein $R^{2A}$ is an unsubstituted $C_{1-6}$ alkyl.

34. The use of Claim 33, wherein $R^{2A}$ is a halogen substituted $C_{1-6}$ alkyl.

35. The use of one of Claims 1-31, wherein $R^{2A}$ is an unsubstituted $C_{2-6}$ alkenyl, an unsubstituted $C_{2-6}$ alkynyl, an unsubstituted $C_{3-6}$ cycloalkyl, an unsubstituted –O–$C_{1-6}$ alkyl or cyano.

36. The use of any one of Claims 1-35, wherein $R^{3A}$ is OH.

37. The use of any one of Claims 1-35, wherein $R^{3A}$ is –OC(=O)$R^{"A}$, wherein $R^{"A}$ is an unsubstituted $C_{1-8}$ alkyl.


38. The use of any one of Claims 1-35, wherein $R^{3A}$ is O-linked alanine or O-linked valine.



















39. The use of any one of Claims 1-38, wherein $R^{5A}$ is hydrogen.




40. The use of any one of Claims 1-38, wherein $R^{5A}$ is halogen.

41. The use of any one of Claims 1-40, wherein $R^{4A}$ is fluoro.














42. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:


































































and

, or a pharmaceutically acceptable salt of the foregoing.













43. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:














,

,

,

,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


44. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,



,

,

,

,
,

,

,

,

,

,




,




,




,




,













,




,



,



,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

45. The use of any one of Claims 1-10, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

46. The use of Claim 45, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

47. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

48. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.